En-tête de navigationNavigation principaleSuiviFiche


Unité de recherche
PCRD EU
Numéro de projet
00.0140
Titre du projet
CANCER and MSI: Novel approaches towards the diagnosis and therapy of tumours with microsatellite instability.
Titre du projet anglais
CANCER and MSI: Novel approaches towards the diagnosis and therapy of tumours with microsatellite instability.

Textes relatifs à ce projet

 AllemandFrançaisItalienAnglais
Mots-clé
-
-
-
Anzeigen
Autre Numéro de projet
-
-
-
Anzeigen
Programme de recherche
-
-
-
Anzeigen
Description succincte
-
-
-
Anzeigen
Autres indications
-
-
-
Anzeigen
Partenaires et organisations internationales
-
-
-
Anzeigen
Résumé des résultats (Abstract)
-
-
-
Anzeigen
Références bases de données
-
-
-
Anzeigen

Textes saisis


CatégorieTexte
Mots-clé
(Anglais)
Colon cancer; HNPCC; microsatellite instability; mismatch repair; chemotherapy;
Life Sciences; Medicine; Health; Scientific Research
Autre Numéro de projet
(Anglais)
EU project number: QLG1-CT-2000-01230
Programme de recherche
(Anglais)
EU-programme: 5. Frame Research Programme - 1.1.8 Generic R&D activities
Description succincte
(Anglais)
See abstract
Autres indications
(Anglais)
Full name of research-institution/enterprise:
Universität Zürich
Institute of Melecular Cancer Research
Partenaires et organisations internationales
(Anglais)
University of Leiden (NL), Istituto Superiore di Sanita (I), Istituto Dermopatico dell'Immaccolata (I), University of Helsinki (FIN), University of Roskilde (DK), Slovak Academy of Sciences (SK)
Résumé des résultats (Abstract)
(Anglais)
A large percentage of tumours from hereditary non-polyposis colon cancer (HNPCC) patients, as well as more than 15% of sporadic colon tumours, display microsatellite instability (MSI) , which has been linked to a defect in mismatch correction (MMR) . Tumour cells with high MSI (MSI-H) differ from other cancer cells: they are largely diploid and the oncogenes and tumour suppressor genes mutated in them are frequently different from those altered in sporadic disease without MSI. We shall compare the response of normal and MSI-H cells to a series of chemotherapeutic and radio-mimetic agents, as well as to ionising and non-ionising radiation. The principal aim of this program is to exploit the identified differences in cancer therapy, by devising ways of selectively killing cells with MSI. The second goal of the study is to use our findings to develop new, facile, diagnostic strategies for the identification of at-risk individuals.
Références bases de données
(Anglais)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 00.0140